Figure 3.

Principal component analysis (PCA) was completed to detect intrinsic clusters between responders to Vigil treatment and γ-IFN-ELISPOT reactivity post-Vigil treatment as well as possible outliers. TIS^HIGH good responders (Tumor inflammation score (TIS)) > 6, OS > 12months) post-Vigil treatment = red; TIS^HIGH poor responders (TIS score > 6, OS < 12months) post-Vigil treatment = blue; TIS^LOW good responders (TIS score < 6, OS > 12months) post-Vigil treatment = green; TIS^LOW poor responders (TIS score < 6, OS < 12months) post-Vigil treatment = purple; γ-IFN-ELISPOT-negative = circles; γ-IFN-ELISPOT-positive = squares; post-Vigil; γ-IFN-ELISPOT not evaluable = triangle (A) Heatmap of immune pathways stratified by TIS status, response to Vigil therapy and γ-IFN-ELISPOT status. Blue scale indicates under-expressed genes and red scale upregulated genes (B).